Our Management Team
Our management team is made up of experienced industry leaders, all of whom feel passionately about improving the lives of people with hemophilia. Together, we are deeply involved in the hemophilia community and are committed to taking meaningful steps forward with patients, doctors, and others in our community. Our team is dedicated to working collaboratively to be catalysts of change in the research, development, manufacturing, and commercialization of coagulation products. With our unique depth of experience and a clear vision, we hope to accelerate the advancement of hemophilia treatment.
Mr Butler has more than 20 years of experience commercializing innovative therapies, most recently leading businesses that serve rare disease patient populations. From 1997 to 2011, Mr Butler held various positions at Genzyme Corporation, one of the world’s largest biotechnology companies. While at Genzyme, he most recently served as President of the company’s rare genetic diseases business, which has developed and commercialized first-to-market, transformative therapies for small patient populations. Mr Butler also led the company’s renal, endocrinology, and cardiovascular businesses, growing the division to $1 billion in revenue. Earlier in his career, he held sales and marketing positions at Amgen and Hoffmann-La Roche. Mr Butler received his BA degree in Chemistry from Manhattan College and his MBA degree from Baruch College. He currently serves on the board of the American Kidney Fund and the Boys and Girls Club of Metrowest.
Mr Corcoran brings extensive quality and biopharmaceutical operations experience to Inspiration, serving most recently as Vice President of Quality at Aegerion Pharmaceuticals. Prior to Aegerion, Mr. Corcoran served as Vice President of Quality at Shire Human Genetic Therapies/TKT, with responsibility for global quality operations spanning six sites. He also spent 12 years at Genetics Institute/Wyeth in positions of increasing responsibility, where he made key contributions to the development and commercialization of hemophilia products. Mr. Corcoran received his M.S. from the University of Massachusetts at Lowell and his B.S. from the Catholic University of America.
Mr Dahan leads commercial development and strategic planning activities for Inspiration. He brings deep experience in biopharmaceutical strategy development as well as execution through business development and internal cross-functional management expertise. He leads global marketing for OBI-1, a recombinant product for two orphan diseases. Prior to joining Inspiration Michel Dahan led global marketing and strategic planning for the hemophilia franchise at Ipsen. He began his career in M&A and corporate business development. He earned his Graduate degree in business administration at HEC Paris (France), his ‘maitrise’ in mathematics from University Paris VI (France), and his executive education program (PLD) at Harvard Business School (Boston, MA).
Dr De Rosch leads and manages activities and relationships with regulatory agencies around the world. Immediately prior to joining Inspiration, Dr De Rosch was Senior Director of Global Regulatory Strategy at Vertex Pharmaceuticals. In this position, he led the global submission team for a new therapy targeting an underlying defect in cystic fibrosis, which was recently approved in the U.S. Before joining Vertex, he served as Director of Regulatory Affairs at Berlex Laboratories, Inc. He began his career as a research chemist at Mallinckrodt Medical, Inc. and Diatide, before transitioning into roles in product development and regulatory affairs. Dr De Rosch earned his Ph.D. at the University of California, San Diego and his B.S. at the University of Wisconsin – Parkside.
Ms Ferraro is responsible for overseeing the global planning, development, implementation and administration of the company’s human resources strategies and programs. Immediately prior to joining Inspiration, Ms Ferraro served as Vice President, Human Resources at PAREXEL International, the global biopharmaceutical services organization. Prior to PAREXEL, she was Global Director of Human Resources at NetGenesis, Axis Communications and Applied Science and Technology. Ms Ferraro is certified nationally as a Global Professional of Human Resources and Senior Professional in Human Resources through the Society for HR, and is a Certified Compensation Professional through World at Work. She received her B.S. in International Business from Franklin Pierce College.
Ms Hadas comes to Inspiration from Genzyme where she spent 10 years, most recently as Senior Corporate Counsel. Ms Hadas provided corporate legal support for Genzyme’s Personalized Genetic Health, Renal, Endocrine and Cardiovascular business units. Prior to Genzyme, she was an Associate at Foley Hoag LLP. At Foley Hoag, Ms Hadas represented pharmaceutical, biotechnology and medical device companies, as well as other healthcare entities. Earlier, she was a law clerk for Chief Justice David Brock of the New Hampshire Supreme Court. Ms Hadas received her B.A. from the University of Michigan and her J.D. from Boston College Law School.
Mr. Keavany brings over 15 years of hemophilia commercial experience to Inspiration. Most recently, Mr. Keavany served as Vice President of Sales and Operations at CSL Behring, where he led three sales teams and launched six products in a variety of rare diseases, including hemophilia. Before joining CSL, he served as Vice President of Specialty Sales at Wyeth. In this position, he led their Hemophilia, Oncology and Transplant teams. Earlier in his career, he helped build Genetics Institute’s first sales organization and launched the first recombinant FIX. He previously spent 15 years with Zeneca in positions of increasing responsibility in Sales, Marketing and Managed Care. Mr. Keavany received his B.S. from Western New England College.
As Vice President, Process Sciences, Dr. Schauer will work across teams at Inspiration to further develop the company’s scientific, technical and operational capabilities. Before joining Inspiration, he served as Senior Director, Process Development, Global Biologics Research and Development at Hospira, where he held primary responsibility for the technical oversight of drug substance and drug product process development activities for Hospira's growing portfolio of biosimilar products. Dr. Schauer also served previously as Director, DSP Research and Development at Millipore Corporation. Earlier in his career, Dr. Schauer built experience in process development and manufacturing sciences with positions at Lexigen/EMD (Merck) and Biogen Idec, following 13 years at Genetics Institute/Wyeth in roles of increasing responsibility. Dr. Schauer earned his Ph.D. at Virginia Polytechnic Institute and State University.
Ms Tubridy has over 20 years’ experience in directing global clinical programs, developing regulatory and clinical strategies, and leading development programs of novel and first in class biologics and monoclonal antibodies, with a particular focus on hematology/oncology. Ms Tubridy most recently served as Executive Director, Clinical Operations and Regulatory Affairs, Translational Medicine at Alexion Pharmaceuticals. She served in this same role at Taligen until its acquisition by Alexion. Before Taligen, Ms Tubridy was Senior Director, Clinical Operations at Biogen Idec Hemophilia and Vice President, Clinical Operations of Syntonix Pharmaceuticals. In these positions, she developed the clinical program strategy and provided operational support for the companies’ hemophilia programs. Ms Tubridy also held positions at AVANT Immunotherapeutics, Wyeth, Genetics Institute where she was responsible for the hemophilia global medical affairs programs and New England Medical Center. Ms Tubridy received her BSc and PharmD from Massachusetts College of Pharmacy and Allied Health Sciences.